The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so braa 1 and two palb 2 cze 2 ATM account for 10% of breast cancer cases these are the these are not these are the exception and not the rule but they are germline mutations they're single gene mutations and they're worth screening for
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
PALB2 which uh is a partner of the bracket 2 protein and about 1% of all breast cancers will have a palb2 mutation which is a a mutation that also substantially increases the risk of developing lifetime breast cancer but a little bit less than brca 1 or two about 1 to 2% will be related to a uh a gene called uh Che 2 chek2 which also increases risk of colon cancer and about 1 to 2% will be related to mutations in the Axia Tangi Asia Gene the ATM mutations
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.